↓ Skip to main content

Randomized Phase II study of the safety, efficacy and immune response of GVAX pancreas (with cyclophosphamide) and CRS-207 with or without nivolumab in patients with previously treated metastatic…

Overview of attention for article published in Journal for Immunotherapy of Cancer, November 2015
Altmetric Badge

About this Attention Score

  • Average Attention Score compared to outputs of the same age

Mentioned by

twitter
3 tweeters

Citations

dimensions_citation
6 Dimensions

Readers on

mendeley
8 Mendeley
You are seeing a free-to-access but limited selection of the activity Altmetric has collected about this research output. Click here to find out more.
Title
Randomized Phase II study of the safety, efficacy and immune response of GVAX pancreas (with cyclophosphamide) and CRS-207 with or without nivolumab in patients with previously treated metastatic pancreatic adenocarcinoma (STELLAR)
Published in
Journal for Immunotherapy of Cancer, November 2015
DOI 10.1186/2051-1426-3-s2-p155
Authors

Dung T Le, Todd S Crocenzi, Jennifer N Urum, Eric R Lutz, Daniel A Laheru, Elizabeth A Sugar, Robert H Vonderheide, George A Fisher, Andrew H Ko, Aimee L Murphy, Katherine McDougall, Sandy Ferber, Dirk G Brockstedt, Elizabeth M Jaffee

Twitter Demographics

The data shown below were collected from the profiles of 3 tweeters who shared this research output. Click here to find out more about how the information was compiled.

Mendeley readers

The data shown below were compiled from readership statistics for 8 Mendeley readers of this research output. Click here to see the associated Mendeley record.

Geographical breakdown

Country Count As %
Unknown 8 100%

Demographic breakdown

Readers by professional status Count As %
Researcher 3 38%
Student > Ph. D. Student 2 25%
Student > Master 2 25%
Unknown 1 13%
Readers by discipline Count As %
Biochemistry, Genetics and Molecular Biology 2 25%
Medicine and Dentistry 2 25%
Agricultural and Biological Sciences 1 13%
Psychology 1 13%
Immunology and Microbiology 1 13%
Other 0 0%
Unknown 1 13%

Attention Score in Context

This research output has an Altmetric Attention Score of 2. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 05 November 2015.
All research outputs
#11,624,419
of 19,140,651 outputs
Outputs from Journal for Immunotherapy of Cancer
#1,587
of 2,098 outputs
Outputs of similar age
#145,522
of 297,060 outputs
Outputs of similar age from Journal for Immunotherapy of Cancer
#76
of 108 outputs
Altmetric has tracked 19,140,651 research outputs across all sources so far. This one is in the 38th percentile – i.e., 38% of other outputs scored the same or lower than it.
So far Altmetric has tracked 2,098 research outputs from this source. They typically receive a lot more attention than average, with a mean Attention Score of 14.1. This one is in the 23rd percentile – i.e., 23% of its peers scored the same or lower than it.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 297,060 tracked outputs that were published within six weeks on either side of this one in any source. This one has gotten more attention than average, scoring higher than 50% of its contemporaries.
We're also able to compare this research output to 108 others from the same source and published within six weeks on either side of this one. This one is in the 29th percentile – i.e., 29% of its contemporaries scored the same or lower than it.